Insider Transactions in Q2 2024 at Immunovant, Inc. (IMVT)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 22
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,247
-0.72%
|
$94,163
$29.65 P/Share
|
|
May 22
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
16,163
-1.54%
|
$468,727
$29.65 P/Share
|
|
May 22
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,042
-1.12%
|
$117,218
$29.65 P/Share
|
|
May 22
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,242
-0.94%
|
$94,018
$29.65 P/Share
|
|
May 22
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,247
-0.86%
|
$94,163
$29.65 P/Share
|
|
Apr 24
2024
|
Jay S Stout Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
7,239
-4.67%
|
$202,692
$28.9 P/Share
|
|
Apr 24
2024
|
Michael Geffner Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,261
-2.25%
|
$91,308
$28.9 P/Share
|
|
Apr 24
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,963
-1.14%
|
$110,964
$28.9 P/Share
|
|
Apr 17
2024
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
8,280
-0.54%
|
$240,120
$29.37 P/Share
|
|
Apr 17
2024
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,827
-1.38%
|
$284,983
$29.37 P/Share
|
|
Apr 17
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,253
-1.66%
|
$355,337
$29.37 P/Share
|
|
Apr 17
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
34,079
-1.58%
|
$988,291
$29.37 P/Share
|
|
Apr 17
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,115
-1.1%
|
$293,335
$29.37 P/Share
|
|
Apr 09
2024
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,053
-0.23%
|
$32,643
$31.18 P/Share
|
|
Apr 09
2024
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,689
-0.98%
|
$114,359
$31.18 P/Share
|
|
Apr 09
2024
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,807
-0.44%
|
$149,017
$31.18 P/Share
|
|
Apr 02
2024
|
Douglas J. Hughes Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+8.26%
|
-
|
|
Apr 02
2024
|
Andrew J. Fromkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+10.12%
|
-
|
|
Apr 02
2024
|
Atul Pande Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+10.65%
|
-
|
|
Apr 02
2024
|
George V Migausky Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+8.51%
|
-
|
|
Apr 02
2024
|
Frank Torti Director |
BUY
Grant, award, or other acquisition
|
Direct |
120,400
+15.92%
|
-
|
|
Apr 02
2024
|
William L. Macias Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+12.47%
|
-
|
|
Apr 02
2024
|
Mark S. Levine Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+13.35%
|
-
|
|
Apr 02
2024
|
Jay S Stout Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+26.19%
|
-
|
|
Apr 02
2024
|
Michael Geffner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+27.51%
|
-
|
|
Apr 02
2024
|
Eva Renee Barnett Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+12.77%
|
-
|
|
Apr 02
2024
|
Julia G. Butchko Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
54,978
+10.62%
|
-
|
|
Apr 02
2024
|
Peter Salzmann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
160,534
+12.82%
|
-
|